Tumor Angiogenesis: Basic Mechanisms and Cancer Therapy by Dieter MarméTumor Angiogenesis: Basic Mechanisms and Cancer Therapy by Dieter Marmé

Tumor Angiogenesis: Basic Mechanisms and Cancer Therapy

EditorDieter Marmé, Norbert Fusenig

Hardcover | October 15, 2007

Pricing and Purchase Info


Earn 2,660 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


Tumor angiogenesis is one of the most prominent mechanisms driving tumor development and progression. Since its discovery more than 30 years ago some of the most important signaling pathways linking specific angiogenic activities of the tumor cells to the fatal reactions of the patient's vascular system have been elucidated. As a consequence crucial targets for therapeutic intervention have been identified and validated.Based on these efforts and achievements, targeted drug development programs have been implemented to interfere with tumor angiogenesis as an attractive strategy in cancer treatment.As a promising result the first targeted anti-angiogenic drugs have been approved for a variety of solid metastasizing cancers. The first generation of these molecules targets the two most prominent regulatory components of tumor angiogenesis: the vascular endothelial growth factor (VEGF), produced by tumor cells, and the VEGF receptor tyrosine kinase, which is expressed on vascular endothelial cells.Part 1 of this volume describes the basic mechanisms of tumor angiogenesis. Beyond the VEGF/VEGF receptor system, additional tumor-angiogenic systems are presented as new potential targets for anti-angiogenic therapy. Part 2 reviews the efforts made in preclinical research to validate new targets and to show efficacy in animals. Part 3 is entirely devoted to the clinical development of the novel anti-angiogenic drugs and their current use in clinical practice.
Title:Tumor Angiogenesis: Basic Mechanisms and Cancer TherapyFormat:HardcoverDimensions:863 pagesPublished:October 15, 2007Publisher:Springer Berlin HeidelbergLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:354033176X

ISBN - 13:9783540331766

Look for similar items by category:


Table of Contents

Historical Overview: Tumor angiogenesis: From bench to bedside.- Mechanisms: Vasculogenesis and angiogenesis in development. Guidance of vascular and neuronal network formation. The angiogenic switch in tumorigenesis. Pathophysiology and clinical implications of vascular endothelial growth factor. Regulation of angiogenesis and vascular homeostasis through the Angiopoietin/Tie system. Eph receptors and ephrins: role in vascular development and tumor angiogenesis. The role of the neuropilins and their associated plexin receptors in tumor angiogenesis and tumor progression. PDGF: impact on physiological and tumor angiogenesis. Hypoxia and tumour angiogenesis. Hypoxia and angiogenesis in GBM. Endogenous inhibitors of angiogenesis. Thrombospondins and angiogenesis. Molecular and cellular aspects of heparanase. Vessel maturation and perivascular cells. Adhesion molecules in the vascular cell cross-talk. Homing and differentiation of endothelial progenitor cells. Molecular players in lymphangiogenesis. The relationship between tumors and the lymphatics: consequences for metastasis. Inflammation and angiogenesis: innate immune cells as modulators of tumor vascularization. Arteriovenous malformation in mice and men.- Animal Models and Preclinical Anti-Angiogenic Studies: VEGF antibodies for anti-angiogenic therapy. VEGF receptor tyrosine kinase inhibitors for the treatment of cancer. VEGF receptor antibodies for anti-angiogenic therapy. Angiopoietin-2 antagonists for anti-angiogenic therapy. Anti-angiogenic therapy with thrombospondins. The use of orthotopic models to validate anti-vascular therapies for cancer. Vascular tumor targeting. Molecular imaging of targets and therapeutics in tumor angiogenesis. Imaging of tumor angiogenesis and anti-angiogenesis. Visualization of microcirculation anti-angiogenic tumor therapy. Cellular actions of angiogenesis inhibitors on blood vessels. Anti-angiogenic therapy for normalization of tumor vasculature and microenvironment. Metronomic anti-angiogenic chemotherapy: questions and answers.- Anti-Angiogenic Tumor Therapy in Clinical Studies: Clinical development of Avastin. Clinical development of Sorafenib (BAY 43-9006), a VEGF-R/RAF inhibitor. Clinical development of the VEGFR signalling inhibitor AZD2171. Clinical development of Sunitinib Malate. The EGF(R) and VEGF(R) pathways as combined targets for anti-angiogenesis trials in cancer therapy. Imaging the effect of anti-angiogenic tumor therapy in clinical studies. ZD6474: preclinical and clinical development. Integrins: targets for anti-angiogenic therapy. Thalidomide in multiple myeloma. Surrogate markers of angiogenesis. Vascular disrupting agents in cancer therapy.

Editorial Reviews

From the reviews:"The chapters in Tumor Angiogenesis are divided into four sections . . Tumor Angiogenesis is an outstanding overview of the basic science and translational aspects of angiogenesis. . To fully capitalize on antiangiogenic therapy, we must continue to have an open dialogue between basic scientists and clinical investigators. This book will serve that purpose, not only for graduate students and new investigators in the field, but also for experienced investigators." (Lee M. Ellis, The New England Journal of Medicine, May, 2008)